Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
about
Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for cliniciansCYP2D6 polymorphisms and their influence on risperidone treatmentAsenapine: a novel psychopharmacologic agent with a unique human receptor signatureDopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population.Pharmacogenomics: a path to predictive medicine for schizophrenia.Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.Genomics and the future of pharmacotherapy in psychiatry.Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administrationIndividual differences in the sensitivity to serotonergic drugs: a pharmacobehavioural approach using rats selected on the basis of their response to novelty.Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia.Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia.Association analysis of TPH2, 5-HT2A, and 5-HT6 with executive function in a young Chinese Han population.No observable relationship between the 12 genes of nervous system and reasoning skill in a young Chinese Han population.Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers
P2860
Q24657338-0C720C5B-7D4A-4111-8CFE-B62CD611B574Q28079227-A2B7AFF3-B658-4B7D-A3D0-85FA19B2A8AEQ28270767-9D8BE7D4-6F69-46EF-823A-5C7DD2BBD2FBQ34544566-EA40AD7C-CF32-4F74-9076-F5AA77717372Q35939972-694260FF-3F7D-41AF-9066-F075374F3069Q36341739-4D0CA77D-4281-4E46-9033-9EFB4BE76B20Q36946132-CE7BCD47-CE48-457F-B496-2770FFFF5EACQ36951758-CFFA5F7D-0688-4EEF-AD87-0267ED895B61Q37012177-617436DF-784F-4719-BE78-88F74A72FD58Q37265383-ECD08655-CAFF-47BB-9172-28842B1C87BAQ40069536-D624F2AB-9F65-4EEC-85B6-53251776D58EQ43561584-5E6B49E4-6AEB-4E2D-BDB2-D86A1E0812D5Q45918280-F0B98BD5-A8AE-4115-BD2E-EDEDC95E13E0Q47139082-49DE7DAC-C559-4BFE-9EBD-AB91B2A49EBCQ51874685-40773172-1C5E-442F-90F1-B64864C944D8Q51891355-05D0A863-F2B0-4AAD-80D7-F7AF69A7A373Q57212204-FBBB8AF9-EB72-4DB7-9F20-39E541F61256
P2860
Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pharmacogenetic studies of res ...... newer atypical antipsychotics.
@ast
Pharmacogenetic studies of res ...... newer atypical antipsychotics.
@en
type
label
Pharmacogenetic studies of res ...... newer atypical antipsychotics.
@ast
Pharmacogenetic studies of res ...... newer atypical antipsychotics.
@en
prefLabel
Pharmacogenetic studies of res ...... newer atypical antipsychotics.
@ast
Pharmacogenetic studies of res ...... newer atypical antipsychotics.
@en
P2093
P2860
P356
P1433
P1476
Pharmacogenetic studies of res ...... newer atypical antipsychotics.
@en
P2093
Cheng-Chun Lee
Hsien-Yuan Lane
Wen-Ho Chang
Yi-Ching Liu
P2860
P304
P356
10.1517/14622416.6.2.139
P577
2005-03-01T00:00:00Z